Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2021-08-30 Board/Management Inform…
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 24, 2021, reporting the appointment of a new Vice President, Corporate Controller / Chief Accounting Officer. The content focuses on management changes, including biographical details, compensation, and indemnification agreements. There is no financial data or report attached, nor is it an announcement of a report publication. The primary subject is a change in senior management, which fits the Board/Management Information category (MANG).
2021-08-30 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is under Item 5.02, which reports the departure of a principal accounting officer and transition of roles. This clearly relates to changes in senior management. The document does not contain financial statements or detailed financial data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not an announcement of voting results, capital changes, or legal proceedings. The primary focus is on management changes, fitting the Board/Management Information category (MANG). The document length is short and focused on this event, confirming the classification.
2021-08-19 English
PRIMARY DOCUMENT
Director's Dealing
2021-08-17 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-09 English
PRIMARY DOCUMENT
Director's Dealing
2021-08-03 English
PRIMARY DOCUMENT
Director's Dealing
2021-08-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.